What are the 4 diseases of the eye

While hundreds of eye conditions exist, four major disease categories pose the greatest threat to vision worldwide: cataracts, glaucoma, diabetic retinopathy, and age-related macular degeneration. These conditions represent leading causes of visual impairment and blindness globally, affecting millions and requiring different prevention and treatment approaches.

Cataracts involve progressive clouding of the eye's natural crystalline lens, resulting from protein breakdown and aggregation that scatters rather than transmitting light clearly. Cataracts represent the leading cause of reversible blindness worldwide, affecting more than 24 million Americans over 40 and causing approximately half of all blindness globally. Risk factors include advancing age (the primary factor, with prevalence approaching 70% in those over 75), prolonged UV exposure damaging lens proteins through photochemical reactions, smoking (which doubles cataract risk through oxidative stress), diabetes (causing metabolic changes that accelerate lens protein modifications), eye trauma or inflammation, genetic factors, and certain medications especially long-term corticosteroid use. Symptoms develop gradually over months to years and include progressively blurred vision, increased glare and halos around lights (particularly troublesome for night driving), faded color perception, and sometimes temporary improvement in near vision ("second sight") as the lens swells in early cataract formation. While early cataracts may be managed with updated glasses prescriptions and brighter lighting, surgery becomes necessary when visual impairment interferes with daily activities. Modern cataract surgery involves removing the clouded lens and implanting an artificial intraocular lens, achieving success rates exceeding 95% with recovery typically measured in days to weeks. Advanced lens implant options can correct not only cataracts but also pre-existing refractive errors and presbyopia, potentially reducing dependence on glasses.

Glaucoma encompasses a group of diseases causing progressive optic nerve damage, typically associated with elevated intraocular pressure (IOP), representing the leading cause of irreversible blindness worldwide. The most common form, primary open-angle glaucoma, develops gradually and painlessly, usually starting with peripheral vision loss that patients often don't notice until substantial damage has occurred. Acute angle-closure glaucoma, conversely, causes sudden severe symptoms including eye pain, headache, nausea, blurred vision, and halos around lights, constituting a medical emergency requiring immediate treatment to prevent permanent vision loss. Risk factors include elevated IOP (though glaucoma can occur with normal pressure), age over 60, family history, African, Hispanic, or Asian ancestry, thin corneas, extreme nearsightedness or farsightedness, previous eye trauma, and certain medical conditions including diabetes and high blood pressure. Because early glaucoma causes no symptoms, regular comprehensive eye examinations with tonometry (pressure measurement) and optic nerve evaluation are essential, particularly for those with risk factors. Treatment focuses on lowering IOP through medications (eye drops that reduce fluid production or increase drainage), laser procedures opening drainage channels, or surgery creating new drainage pathways. While existing damage cannot be reversed, treatment can halt or slow progression, preserving remaining vision. Vision loss from glaucoma, once it occurs, is permanent, emphasizing the critical importance of early detection through screening before symptoms develop.

Diabetic retinopathy results from diabetes-induced damage to retinal blood vessels, representing the leading cause of blindness in working-age adults in developed countries. Both Type 1 and Type 2 diabetes can cause retinopathy, with risk increasing with diabetes duration, poor blood sugar control, high blood pressure, high cholesterol, and pregnancy. The condition progresses through stages: mild nonproliferative retinopathy (early microaneurysms and small vessel changes visible on examination but causing no symptoms), moderate to severe nonproliferative retinopathy (progressive vascular damage including vessel leakage and blockage reducing blood supply to the retina), and proliferative diabetic retinopathy (advanced stage where new abnormal blood vessels grow on the retina and into the vitreous, prone to bleeding and causing fibrous scarring that can pull on the retina leading to detachment). Additionally, diabetic macular edema—fluid accumulation in the macula from leaking blood vessels—can occur at any stage, causing blurred central vision. Prevention centers on excellent diabetes management with tight blood sugar control (demonstrated to dramatically reduce retinopathy development and progression), blood pressure control, cholesterol management, and regular dilated eye examinations annually or more frequently as recommended. Early detection enables interventions including laser photocoagulation to seal leaking vessels and prevent abnormal vessel growth, anti-VEGF injections to reduce vessel leakage and prevent abnormal vessel proliferation, and in advanced cases, vitrectomy surgery to remove vitreous hemorrhage and relieve retinal traction.

Age-related macular degeneration (AMD) involves progressive damage to the macula—the central retina providing sharp, detailed vision—becoming the leading cause of severe irreversible vision loss in people over 50 in developed countries. AMD exists in two forms: dry AMD (85-90% of cases) features gradual accumulation of yellowish deposits called drusen beneath the retina, with progressive breakdown of light-sensitive cells and supporting tissue, typically advancing slowly over years; wet AMD (10-15% of cases) involves abnormal blood vessel growth beneath the retina (choroidal neovascularization) that leaks fluid and blood, causing rapid central vision loss, distortion, and scarring. Symptoms include blurred or distorted central vision (straight lines appear wavy), dark or empty areas in central vision, difficulty reading or recognizing faces, and need for brighter light for close work. Risk factors include advancing age (prevalence rises dramatically after 60), smoking (the most significant modifiable risk factor, doubling or tripling AMD risk), family history and genetics (variations in complement factor genes substantially increase risk), race (higher rates in Caucasian populations), obesity, cardiovascular disease, and prolonged sun exposure. While no cure exists for AMD, specific interventions can slow progression or limit vision loss: the AREDS2 vitamin formulation (containing vitamins C and E, lutein, zeaxanthin, zinc, and copper) reduces progression risk in intermediate dry AMD; anti-VEGF injections revolutionized wet AMD treatment by preventing abnormal blood vessel growth and leakage, often stabilizing or even improving vision when administered promptly and regularly; and laser treatments may be appropriate in select cases. Low vision rehabilitation helps maximize remaining vision through magnification devices, enhanced lighting, and adaptive strategies. Regular monitoring using an Amsler grid allows early detection of changes requiring urgent evaluation, particularly the sudden onset of distortion signaling possible wet AMD development requiring immediate treatment for best outcomes.